Investigation Report on China Risedronate Sodium Market, 2010-2019

With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiova…
Reference: 1506244
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
6/25/2015
Pages
30
Version:
2010
Charts:
35
Language
  • English
  • Chinese
Format
License

Description

With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020.
Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included.
As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRI’s market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014.
With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.

Readers can get at least the following information from this report:
-market size of risedronate sodium in China
-competitive landscape of risedronate sodium in Chinese market
-price of risedronate sodium made by different enterprises in China
-market outlook of risedronate sodium in China

The author suggests the following groups of people purchase this report:
-manufacturers of osteoporosis drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service
Table of Contents

1 Related Concepts of Risedronate Sodium
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Risedronate Sodium in China
2.1 Patent and Approval Status of Risedronate Sodium in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Risedronate Sodium in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Risedronate Sodium in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Risedronate Sodium in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Risedronate Sodium in Chinese Hospitals in 2014
6.1 Kunming Jida Pharmaceutical Co., Ltd
6.2 Beijing SL Pharm
6.3 Yangtze River Pharmaceutical Group
6.4 Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
6.5 Topfond (Trade Name: Weishan)

7 Major Manufacturers of Risedronate Sodium in Chinese Market, 2010-2014
7.1 Beijing SL Pharm
7.2 Kunming Jida Pharmaceutical Co., Ltd
7.3 Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd
7.4 Yangtze River Pharmaceutical Group
7.5 Topfond

8 Market Outlook of Risedronate Sodium in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts

Chart Approval Information of Risedronate Sodium in China
Chart Sales Status of Risedronate Sodium in China
Chart Sales Value of Risedronate Sodium in China, 2010-2014
Chart Sales Value of Risedronate Sodium in Some Regions in China, 2010-2014
Chart Sales Volume of Risedronate Sodium in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Made by Kunming Jida in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Made by Jiangsu Chiatai Qingjiang in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Made by Beijing SL in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Made by Other Enterprises in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Tablets in China, 2010-2014
Chart Sales Value and Market Share of Risedronate Sodium Capsules in China, 2010-2014
Chart Price of Risedronate Sodium Made by Kunming Jida Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Risedronate Sodium Made by Beijing SL Pharm in Some Chinese Cities in 2014
Chart Price of Risedronate Sodium Made by Yangtze River Pharmaceutical Group in Some Chinese Cities in 2014
Chart Price of Risedronate Sodium Made by Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Risedronate Sodium Made by Topfond in Some Chinese Cities in 2014
Scroll